Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.50 |
| ▸ | UMPS | P11172 | 5/20 | 0.48 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.48 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
| ▸ | ATIC | P31939 | 2/20 | 0.44 |
| ▸ | GART | P22102 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1364683 | 1.00 | FBP1 (0.50) | FBP1UMPSDNPH1HPRT1P2RY2 | |
| SCHEMBL19370845 | 1.00 | FBP1 (0.50) | FBP1UMPSDNPH1HPRT1P2RY2 | |
| SCHEMBL25834288 | 0.91 | P2RY2 (0.43) | UMPSDNPH1P2RY2P2RY6 | |
| SCHEMBL11178912 | 0.79 | HPRT1 (0.53) | FBP1UMPSDNPH1HPRT1P2RY2 | |
| SCHEMBL31685403 | 0.74 | FBP1 (0.46) | FBP1UMPSDNPH1HPRT1P2RY2 | |
| SCHEMBL11758791 | 0.72 | CDA (0.62) | FBP1UMPSDNPH1HPRT1P2RY2 | |
| SCHEMBL21067752 | 0.72 | NT5E (0.30) | — | |
| SCHEMBL11755358 | 0.72 | CDA (0.62) | FBP1UMPSDNPH1HPRT1P2RY2 | |
| SCHEMBL11755974 | 0.72 | HPRT1 (0.53) | FBP1UMPSDNPH1HPRT1P2RY2 | |
| SCHEMBL11760447 | 0.72 | HPRT1 (0.53) | FBP1UMPSDNPH1HPRT1P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | FBP1 1683/4885UMPS 306/4885DNPH1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.